Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1076344 | 1.00 | MAPT (0.47) | MAPTHSD17B10CYP1A2CYP3A4KDM4E | |
| SCHEMBL1077008 | 0.89 | ESR1 (0.39) | HSD17B10CYP1A2CYP3A4ALOX15HPGD | |
| SCHEMBL2146217 | 0.88 | HPGD (0.43) | HSD17B10CYP1A2CYP3A4ALOX15HPGD | |
| SCHEMBL1077169 | 0.88 | GAA (0.44) | HSD17B10CYP1A2CYP3A4KDM4EALOX15 | |
| SCHEMBL30386360 | 0.88 | HDAC6 (0.40) | MAPTHSD17B10CYP1A2CYP3A4KDM4E | |
| SCHEMBL1076740 | 0.88 | HDAC6 (0.40) | MAPTHSD17B10CYP1A2CYP3A4KDM4E | |
| SCHEMBL1074111 | 0.88 | ESR1 (0.38) | MAPTHSD17B10CYP1A2CYP3A4KDM4E | |
| SCHEMBL30386259 | 0.88 | ESR1 (0.38) | MAPTHSD17B10CYP1A2CYP3A4KDM4E | |
| SCHEMBL1075535 | 0.87 | ESR1 (0.39) | HSD17B10CYP1A2CYP3A4ALOX15HPGD | |
| SCHEMBL30386550 | 0.87 | ESR1 (0.39) | HSD17B10CYP1A2CYP3A4ALOX15HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11628146-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11628146-B2 | Estrogen receptor ligand treatment for neurodegenerative diseases | ESR2, ESRRG, ESR1 | MAPT 289/4885HSD17B10 782/4885CYP1A2 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.